Table 4.
Relapse according to patient characteristics at baseline (n = 283) n (%)
| Relapse (n = 49) | No relapse (n = 234) | P value | |
| Relapse | 49 (17.3) | 234 (82.7) | |
| Demographics | |||
| Sex | |||
| Male | 14 (12.4) | 99 (87.6) | 0.074 |
| Female | 35 (20.6) | 135 (79.4) | |
| Age | |||
| mean ± SD | 50.4 ± 8.5 | 46.0 ± 10.2 | 0.006 |
| Median (range) | 50.00 (34.0-66.0) | 48.00 (11.0-68.0) | 0.011 |
| ≤ 20 | 0 (0) | 4 (100) | 0.013 |
| 21-40 | 7 (10.9) | 57 (89.1) | |
| 41-60 | 34 (17.3) | 162 (82.7) | |
| > 60 | 8 (42.1) | 11 (57.9) | |
| Pre-treatment/comorbidities | |||
| HCV/HIV coinfection | 0 (0) | 3 (100) | 0.426 |
| Diabetes mellitus | 2 (8.7) | 21 (91.3) | 0.254 |
| Previous alcohol consumption | 9 (17.0) | 44 (83.0) | 0.943 |
| High pretreatment ALT (> 40) | 36 (17.9) | 165 (82.1) | 0.678 |
| High pretreatment Hgb (≥ 12g/dL) | 40 (18.3) | 179 (81.7) | 0.434 |
| High pretreatment WBC (≥ 4000 mm3) | 45 (16.9) | 222 (83.1) | 0.403 |
| High pretreatment platelet (≥ 150000/mm3) | 32 (14.7) | 186 (85.3) | 0.032 |
| High pretreatment albumin (≥ 3.5 g/dL) | 37 (15.0) | 209 (85.0) | 0.009 |
| High pretreatment HCV RNA (≥ 800000 IU/mL) | 36 (20.3) | 141 (79.7) | 0.082 |
| Liver stiffness | |||
| F ≤ 2 | 9 (6.5) | 130 (93.5) | < 0.001 |
| F3-4 | 40 (27.8) | 104 (72.2) | |
| IL28B polymorphism | |||
| rs8099917TT | 42 (17.3) | 201 (82.7) | 0.592 |
| rs8099917Non-TT | 5 (21.7) | 18 (78.3) | |
| Unknown | 2 (11.8) | 15 (88.2) | 0.918 |
| rs12979860CC | 40 (17.2) | 193 (82.8) | 0.569 |